Table 3.

Association of Cardiac Hemodynamic Measures With Brain Volumes: AGES‐RS Imaging Cardiac Evaluation to Locate Areas of Necrosis and Detect MI (ICELAND‐MI)

	Total Brain Parenchyma		Gray Matter		White Matter
	Beta* (95% CI)	P Value	Beta* (95% CI)	P Value	Beta* (95% CI)	P Value
LVEF
Model 1	−5.1 (−11.4, 1.1)	0.11	−4.2 (−8.1, −0.3)	0.03	−0.6 (−3.6, 2.2)	0.65
Model 2	−1.8 (−5.6, 1.9)	0.34	−1.5 (−4.5, 1.4)	0.31	−0.5 (−2.4, 1.5)	0.62
LVSV
Model 1	−7.5 (−11.5, −3.4)	<0.001	−6.1 (−8.6, −3.6)	<0.001	−1.4 (−3.2, 0.5)	0.15
Model 2	−4.4 (−6.9, −1.9)	<0.001	−3.7 (−5.7, −1.8)	<0.001	−1.1 (−2.4, 0.2)	0.09
CO
Model 1	−8.7 (−4.4, −3.0)	0.002	−8.0 (−11.5, −4.4)	<0.001	−0.9 (−3.6, 1.8)	0.50
Model 2	−3.9 (−7.4, −0.4)	0.030	−3.9 (−6.7, −1.2)	0.005	−0.3 (−2.1, 1.5)	0.76

Model 1: adjusted for age and sex; Model 2: adjusted for age, sex, education, current smoker, intracranial volume, history of hypertension, diabetes mellitus, systolic blood pressure, prevalent coronary heart disease, stroke, total cholesterol, body mass index, atrial fibrillation. AGES‐RS indicates age, gene/environment susceptibility‐Reykjavik Study; CO, cardiac output; LVEF, left ventricular ejection fraction; LVSV, left ventricular stroke volume; MI, myocardial infarction.

^*Betas represent change in the brain volumes for each 10% lower LVEF, 10 mL lower LVSV and 1 L/min lower CO.